招商通知： 2025年9月4-5日，第三届全球手术机器人大会 2025年8月14日， 飞利浦宣布将在美国本土追加超 1.5亿美元 （约合10.7亿人民币）投资 ，用于 扩展AI赋能的超声设备制造能力 与相关研发项 目。此次投资包括对宾夕法尼亚州Reedsville工厂的扩建，以及明尼苏达州Plymouth影像引导治疗基地的持续升级，重点围绕AI驱动的超声系统定 制、图像引导设备制造和专业人才培训三大方向展开。 这项计划，被视为飞利浦推动AI医疗落地、重构本地制造体系的重要一步，也标志着其在经历Respironics事件与多轮结构调整后，正在以更具韧性 的节奏重回创新主航道。 飞利浦北美区负责人Jeff DiLullo表示："我们每年在美国的研发投入达9亿美元。 此次新增投资不仅将带动本地就业，更将加速AI技术与临床场景的 深度融合，为患者提供更高效、精准的诊疗方案。 " 此次动作，也被视为飞利浦在2025年下半年业务修复期中的又一关键布局。继Q2财报公布后，尽管整体收入小幅下降，但AI驱动的诊断与治疗业务 板块利润率持续改善，成为公司结构性回稳的关键支点。 # 战略落地的另一面：AI不只在"云端"，也要回到" ...

Philips is investing more than $150 million toward U.S. manufacturing and research and development with the goal of expanding the production of AI-powered health technology innovations.  While it's far from the company's first investment in its domestic operations, it aligns with the Trump administration's goals of boosting domestic manufacturing and helping the U.S. become less reliant on foreign goods. Part of its latest investment includes the expansion of its Reedsville, Pennsylvania, manufacturing faci ...

本报（chinatimes.net.cn）记者张智 北京报道 距2025年中国国际服务贸易交易会（服贸会）开幕还有40天！ 据了解，服贸会自创办以来，不仅成为中国推进高水平对外开放的"金字招牌"，为全球企业提供了共 享"中国机遇"的窗口，更逐渐成长为全球服务贸易领域的思想交汇高地、行业方案策源地与创新实践孵 化地，为企业提供了展示创新成果、拓展生态合作的重要窗口。 8月1日，2025年服贸会成果发布活动媒体通气会在京举行。中国饭店协会、安永、飞利浦、施耐德电 气、阿迈特医疗器械、百望股份等行业领军企业负责人悉数到场，提前带来多项创新技术和创新应用产 品。 两项标准、两个指数将亮相 近年来，酒店餐饮行业是服务贸易增长的重要领域。 "我们是服务消费高质量发展的一个重要的行业，有责任推动服务消费高质量发展。"中国饭店协会副会 长丁志刚在会上对包括《华夏时报》在内的记者表示。 据了解，本届服贸会期间，将正式发布国内首个"中国住宿业消费指数"和"中国餐饮业消费指数"。该标 准聚焦住宿餐饮业品质提升和品牌培育，充分激发消费活力，创新培育消费场景，聚焦价格指数、客流 指数、信心指数三个方面，以及成交价格、入住率或成交订单量 ...

Core Viewpoint - Philips reported a sales revenue of €4.34 billion (approximately ¥36 billion) for Q2 2025, a year-on-year decline of 2.8%, but adjusted EBITA reached €540 million with a profit margin of 12.4%, an increase of 130 basis points year-on-year, indicating a recovery in overall profitability and operational efficiency [1][2][25]. Group 1: Financial Performance - The company achieved a nominal sales growth of -3% and a comparable sales growth of 1% in Q2 2025 [2]. - Adjusted EBITA for Q2 2025 was €540 million, representing 12.4% of sales, compared to 11.1% in Q2 2024 [2][3]. - Free cash flow turned positive at €230 million, despite a net profit decline of 46.9% year-on-year [1]. Group 2: Business Segments - The Diagnostics and Treatment segment generated sales of €2.08 billion, down 4% year-on-year, but adjusted EBITA improved to €281 million with a profit margin of 13.5% [3][4]. - The Connected Care segment reported sales of €1.27 billion, a decline of 5%, yet adjusted EBITA rose to €132 million, with a profit margin of 10.4% [11][12]. - The Personal Health segment continued to grow, achieving sales of €862 million, a nominal increase of 3% and a comparable increase of 6% [17][18]. Group 3: Innovation and Product Development - Philips accelerated commercialization of AI-enabled imaging platforms, with the SmartSpeed Precise MRI platform receiving FDA approval, enhancing scanning speed by three times and image clarity by 80% [4][6]. - The company is focusing on AI-driven virtual monitoring capabilities, with key products like Patient Information Center iX and IntelliVue series gaining traction in North America and Europe [11][14]. - New product lines in high-end diagnostics, intraoperative, rapid testing, and remote care are being developed, forming a comprehensive AI-driven "smart device loop" [22][24]. Group 4: Market Strategy - Philips is establishing a global market strategy characterized by breakthroughs in Southeast Asia, a waiting phase in China, and stability in North America [19][21]. - A significant milestone was achieved with a multi-year agreement with the Indonesian Ministry of Health to deploy Azurion imaging systems nationwide, impacting over 280 million people [20]. - The Chinese market is currently adjusting, with a slight decline in sales, but government initiatives may stimulate demand recovery in the second half of the year [21].

Market Overview - US stock index futures are all up, with Dow futures rising by 0.13%, S&P 500 futures by 0.30%, and Nasdaq futures by 0.47% [1] - European indices also show positive movement, with Germany's DAX up 1.17%, UK's FTSE 100 up 0.55%, France's CAC40 up 1.10%, and the Euro Stoxx 50 up 1.02% [2][3] - WTI crude oil increased by 0.07% to $66.76 per barrel, while Brent crude oil rose by 0.13% to $69.41 per barrel [3][4] Federal Reserve Insights - The Federal Reserve is not yet prepared to lower interest rates, with officials divided on the timing and evidence needed for such a decision [5] - The upcoming cryptocurrency policy report from the White House is anticipated to be a catalyst for the crypto market, alongside the Fed's interest rate decision [5] Company News - Oppenheimer raised its year-end target for the S&P 500 to 7100 points, citing easing trade tensions and strong corporate earnings, indicating an 11% upside from the latest closing price [6] - Novo Nordisk lowered its 2025 sales growth and profit expectations, projecting sales growth of 8%-14% compared to a previous forecast of 13%-21% [7] - UnitedHealth's second-quarter earnings guidance fell short of expectations, forecasting adjusted EPS of at least $16, significantly below the analyst consensus of $20.40 [8] - UPS refrained from providing earnings guidance due to market volatility, reporting Q2 revenue of $21.2 billion, a 2.8% year-over-year decline [8][9] - Stellantis restored its earnings guidance but warned of a €1.2 billion (approximately $1.4 billion) tariff impact in the second half of the year [9] - Nomura Holdings reported a 52% year-over-year increase in Q1 net profit, driven by strong trading and investment banking performance [10] - Barclays announced a 23% increase in first-half profits and a $1.3 billion stock buyback plan, benefiting from market trading activity [11] - Whirlpool's Q2 sales fell 5.4% to $3.77 billion, below market expectations, and it lowered its full-year EPS guidance [12] - Philips slightly raised its adjusted operating margin forecast for the year, indicating that the impact of trade tensions was less severe than previously feared [13] Economic Data and Events - Upcoming economic data includes the US wholesale inventory month-on-month change and the Conference Board Consumer Confidence Index [14][15] - Earnings reports are expected from Visa, Booking, Starbucks, UBS, Rio Tinto, UMC, New Oriental, and HSBC [17]

Financial Data and Key Metrics Changes - Order intake grew by 6%, building on a 9% increase from the previous year [6] - Comparable sales increased by 1%, with a margin expansion of 130 basis points to 12.4% [7][32] - Adjusted EBITA margin range increased to between 11.3% and 11.8% for 2025, reflecting a 50 basis points increase [7][39] - Free cash flow for the full year is expected to be between €200 million and €400 million [8][40] Business Line Data and Key Metrics Changes - Diagnosis and Treatment (D&T) comparable sales decreased by 1% due to a high comparison base, but EBITA margin improved by 130 basis points to 13.5% [26][27] - Connected Care saw a 1% decline in comparable sales, with an EBITA margin improvement of 160 basis points to 10.4% [28] - Personal Health experienced strong growth across most geographies, although EBITA margin declined by 170 basis points to 15.2% due to increased costs [30] Market Data and Key Metrics Changes - Strong double-digit growth in North America and growth geographies for order intake [8][10] - China showed subdued consumer sentiment, impacting Personal Health sales, but there are signs of recovery [18][23] - Overall growth was supported by growth geographies, offset by a decline in China [31] Company Strategy and Development Direction - The company is focused on accelerating profitable growth and unlocking the full potential of its segments [42] - Emphasis on innovation and productivity measures to drive gross margins and operational efficiency [7][34] - Plans to host a Capital Markets Day in February to outline the next phase of strategy [42] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the second half of the year, supported by order intake momentum and a robust order book [43] - The tariff landscape remains dynamic, with expected impacts on margins in the second half of the year [39][40] - Management remains cautious about the Chinese market but sees potential for recovery [23][64] Other Important Information - The company has made significant progress in quality management and supply chain reliability, achieving an all-time high service level of 86% [21][20] - The company has achieved €2.1 billion in savings since the start of its three-year plan in 2023 [33] Q&A Session Questions and Answers Question: Can you talk about the improvement in D&T margins? - Management noted a 130 basis points margin expansion driven by gross margin improvements from innovations and productivity measures [49][50] Question: Why have you only banked the tariff improvement and not the EBITA beat in the quarter? - Management indicated that they are happy with the outlook revision but need to accelerate margin expansion in the second half while absorbing tariff impacts [51][52] Question: Can you unpack the decline in Connected Care in the quarter? - The decline was primarily driven by a low single-digit drop in monitoring, but management sees strong demand and order intake growth [53][54] Question: How far along are you in the European market on the system side versus prior to the recall? - Management stated it is too early to provide specific market share numbers but is rebuilding momentum in the market [57] Question: Can you provide color on the growth in ultrasound revenue? - Management indicated slight declines in ultrasound growth but expects performance to strengthen in the second half due to new launches [100] Question: How much of the advertising spend in Personal Health was in price? - Management clarified that pricing in Personal Health is broadly flat, with advertising aimed at driving innovation rather than price reductions [90]

Financial Data and Key Metrics Changes - Order intake grew by 6%, building on a 9% increase from the previous year [5] - Comparable sales increased by 1%, with a margin expansion of 130 basis points to 12.4% [6][30] - Adjusted EBITA margin increased to between 11.3% and 11.8%, reflecting a 50 basis points increase due to recent tariff developments [6][37] - Free cash flow is expected to be between €200 million and €400 million for the full year [7][38] Business Line Data and Key Metrics Changes - Diagnosis and Treatment (D&T) saw a 1% decrease in comparable sales, with strong performance in Image Guided Therapy [25][26] - Connected Care experienced a 1% decline in comparable sales, primarily due to a low single-digit drop in monitoring [27] - Personal Health delivered strong growth across most geographies, although there was a decline in China due to inventory destocking [28][17] Market Data and Key Metrics Changes - North America showed sustained double-digit growth in order intake, while China is recovering slowly with increased tender activity [7][22] - The overall growth was supported by growth geographies, particularly in Europe and Latin America [29] - Customer demand in North America remains strong, with hospitals seeking productivity solutions [20][90] Company Strategy and Development Direction - The company is focused on simplifying operations and enhancing productivity, with a goal of achieving €800 million in productivity savings by 2025 [31][32] - A Capital Markets Day is planned for February 2026 to outline the next phase of the company's strategy [40] - The company aims for mid-single-digit growth and mid-teens margins beyond 2025 [40][66] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the second half of the year, supported by order intake momentum and a robust order book [41] - The tariff landscape remains dynamic, with expected impacts on margins in the second half of the year [36][38] - Management remains cautious about the Chinese market but sees potential for recovery [62] Other Important Information - The company has made significant progress in quality management, reducing field actions and product updates by approximately 20% year-to-date [18] - Service levels reached an all-time high of 86%, improving by more than 10 percentage points year-on-year [19] Q&A Session Summary Question: Can you talk about the improvement in D&T margins? - Management noted a 130 basis points expansion in D&T margins, driven by gross margin improvements and productivity measures [46] Question: Why have you only banked the tariff improvement and not the EBITA beat in the quarter? - Management indicated that they are happy with the outlook revision but need to accelerate margin expansion in the second half while absorbing tariff impacts [49] Question: Can you unpack the decline in Connected Care in the quarter? - The decline was primarily due to a low single-digit drop in monitoring, but demand remains strong with significant partnerships in North America [51][52] Question: How far along are you in the SKU reduction process? - Management stated that SKU reduction is a multiyear process, with ongoing progress across all modalities [105] Question: What parts of the current strategy have been working well? - The company has improved control over patient safety, quality, and supply chain, which has contributed to order intake growth [110]

Q2 2025 Performance Highlights - Order intake increased by 6% year-on-year, and the order book increased by 7% year-on-year[11] - Sales grew by 1%, driven by growth in Personal Health, but partially offset by performance in Diagnosis & Treatment and Connected Care[11] - Adjusted EBITA margin increased by 130 bps to 12.4%[11] - Free cash flow increased from slightly positive to EUR 0.2 billion-0.4 billion, net of Respironics settlement[11] Order Book and Regional Performance - The order book is up 7% year-on-year, with an improved margin profile driven by recently launched innovations[16] - The order book accounts for approximately 40% of revenue[16] Financial Performance by Segment - Diagnosis & Treatment sales decreased by 1%[26] - Connected Care sales decreased by 1%[30] - Personal Health sales grew by 6%[38] Productivity and Outlook - Productivity initiatives delivered EUR 344 million year-to-date and are on track to deliver EUR 800 million in 2025[46] - The adjusted EBITA margin range is increased by 50 bps to 11.3%-11.8%[11]

Group 1 - The company has slightly raised its adjusted operating margin forecast, now expecting it to be between 11.3% and 11.8%, an increase of 50 basis points from previous expectations [1] - In the second quarter, the company's sales grew by 1% year-on-year, reaching €4.3 billion (approximately $4.98 billion) [1] - The company had previously lowered its annual profit forecast in May, attributing it to costs associated with tariffs, estimating potential losses of up to €300 million [1] Group 2 - A report from February indicated that the company paid €38 million in tariffs in the U.S. last year, highlighting the significant impact of tariffs on its operations [2] - The U.S. is the company's largest market, expected to account for about 40% of its sales in 2024, with one-third of its tax payments coming from this market [2] - The company imports various products from China, including respiratory masks and electric shavers, while also sourcing medical equipment from Europe [2]

飞利浦CEO：欧盟与美国的贸易协议提供了清晰的框架，我们可以在此基础上继续发展。美国需求非常 强劲。 ...